A Single Arm, Open-Label, Phase 2 Trial Investigating Nitric Oxide-Inhalation (NO) in Nontuberculous Mycobacteria (NTM) Patients with Mycobacterium Abscessus Complex (MABSC)

Trial Profile

A Single Arm, Open-Label, Phase 2 Trial Investigating Nitric Oxide-Inhalation (NO) in Nontuberculous Mycobacteria (NTM) Patients with Mycobacterium Abscessus Complex (MABSC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Mycobacterium avium complex infections
  • Focus Adverse reactions
  • Acronyms NO-NTM Abscessus
  • Most Recent Events

    • 27 Nov 2017 According to an AIT media release, primary endpoint has been met. (Safety-measured by NO-related serious adverse events (SAEs) over the 21-day treatment period)
    • 27 Nov 2017 Results presented in an AIT Media Release.
    • 21 Nov 2017 According to an AIT media release,management will hold a clinical update meeting on November 28, 2017 to discuss data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top